EPKINLY- epcoritamab-bysp injection, solution

Genmab US, Inc.

EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of:

Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (1.1)
Follicular Lymphoma

adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. (1.2)
These indications are approved under accelerated approval based on response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Store refrigerated at 2°C to 8°C (36°F to 46°F). Keep in the original carton to protect from light. Do not freeze. Do not shake.